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Panax notoginseng saponin (PNS) is one of the key bioactive components of dry root and rhizome of Panax notoginseng 
(Burk.), a well known as Tianqi in Traditional Chinese Medicine (TCM). Although PNS has been shown to possess various 
pharmacological activities, such as being antithrombotic, neuroprotective, anti-inflammatory and hypolipidemic, etc.,  its 
effects on blood glucose levels have not been well documented but for some preliminary reports. It deserves a detailed in 
vivo investigation in animal model. Thus, to investigate the bi-directional regulation of ginsenoside Rgl (Rg1) on blood 
glucose in mice, Rg1 with high purity was prepared from panax notoginseng saponins by normal phase silica gel column 
chromatography and reverse phase C18 preparative chromatography. Normal 4-week-old mice were randomly divided into 
normal control group, normal control group with Rg1, glucose gavage control group, glucose gavage control group with 
Rg1, insulin treated control group and overnight fasting control group with or without Rg1 (n = 10). The mice in the control 
group were intragastrically administered with PBS solution, and the mice in the Rg1 groups were intragastrically 
administered with Rg1 once a day at the doses of 0.5, 1.0 and 1.5 mg/kg for consecutive 7 days. After the last drug, blood 
glucose (BG) levels were measured at 0.5 (30 min) and 1 h after administration using a simultaneous automatic biochemical 
analyzer to observe the effect of Rg1 on BG levels. Compared with the model group, Rg1 significantly decreased the BG 
levels of hyperglycemic mice induced by glucose gavage (P <0.05), significantly increased the BG level of overnight fasted 
mice (P <0.05), and had no significant effects on the normal group of mice. Panax notoginseng saponin Rgl has a significant 
bidirectional regulatory effect on glucose levels in mice. When the blood glucose of mice increases, intragastric 
administration of Rg1 can effectively reduce the blood glucose; conversely, when the blood glucose of mice is low, Rg1 can 
effectively increase the blood glucose value.  
Keywords: Antidiabetic, Bidirectional regulation, Chinese ginseng, Diabetes management, Herbal, Hyperglycemia, 
Hypoglycemia, Notoginsenoside Rgl, Saponin, Tianqi, Traditional medicine 
Panax notoginseng, as a member of the Araliaceae 
family, is a rare Chinese medicinal herb1,2. Its main 
effective component is panax notoginseng saponins 
(PNS), of which the contents of monomeric 
notoginsenoside Rgl and notoginsenoside Rbl are the 
highest and belong to dammarane type tetracyclic 
triterpenoid saponin3-5. According to traditional 
Chinese medicine, PNS and its monomers, Rgl and 
Rbl, are clinically used for cerebral infarction, cerebral 
hemorrhage, and traumatic injury due to their effects of 
promoting blood circulation, removing blood stasis and 
activating blood vessels6,7. With the advancements in 
research, many new pharmacological effects of PNS 
and its monomers have been discovered, such as 
scavenging free radicals, oxygen, and anti-oxidation8,9. 
The incidences of diabetes are increasing 
exponentially. According to a report published by 
International Diabetes Federation (IDF) on 3st 
December 2020, among adults (20–79 years of age), 
there were approximately 625 million people lived 
with diabetes worldwide, and by 2035, the number is 
expected to rise to an estimated 1.01 billion 10. 
Another epidemiological report of 2018 projects that 
the incidence of diabetes had reached 11.6% among 
Chinese adults, while the prevalence of pre-diabetes 
was as high as 50.5%11. With the advance research 
focus on the prevention and treatment of diabetes, it 
has been established that blood glucose management 
is not limited to the target of glycated haemoglobin 
(%HbA1c) percentage and the overall level of blood 
glucose, and blood glucose variation, as an evaluation 
index, has been paid more and more attention by the 
academic community9,10-12. However, the existing 
hypoglycemic drugs could only reduce blood glucose 
unidirectional, and diabetics often face unstable blood 








with the development of the disease13,14. Moreover, 
hypoglycemia has been reported to be more harmful 
than hyperglycemia15. Hyperglycemia for short 
durations poses no threat when compared to 
hypoglycemia, which is rapid and likely to cause coma 
or can prove fatal in severe cases, especially among 
elders with weak perception16,17. Studies have confirmed 
that blood glucose fluctuation is an independent risk 
factor for cardiovascular disease, which triggers oxygen 
stress and promote expression of inflammatory factors, 
and vascular endothelial cell apoptosis, atherosclerosis, 
and islet β cell function damage18,19. Meanwhile, 
increasing evidences have demonstrated that blood 
glucose fluctuation is also an independent risk factor for 
diabetic complications20. Therefore, sustained 
improvements in glycemic control, which not only 
control hyperglycemia, but also prevent hypoglycemia, 
and tries to keep the body’s blood glucose in a stable 
state, is vital in diabetic patients.  
At present, apart from antidiabetic drugs, diet 
regulation, exercise and frequent blood glucose 
monitoring are used to prevent and treat unstable blood 
glucose and hypoglycemia in diabetic patients21. 
However, patients’ non-adherence to recommended 
treatment regimes is influenced by various barriers. 
Diabetes related distress has been identified as a major 
factor responsible for poor adherence to available 
treatment22  Diabetic patients have adapted to 
traditional Chinese medicine (TCM) due to promising 
results in the ailment of diabetes and its associated 
complications.23 Nevertheless, TCM cannot be 
promoted to cure diabetes due to its poor universality 
and inadequate knowledge about its active 
pharmaceutical ingredient24,25. In this study, we tried to 
evaluate whether or not Panax notoginseng saponin 
Rgl holds the potential to bilaterally regulate the blood 
glucose in mice.  
 
Materials and Methods 
 
Chemicals and animals 
Panax notoginseng saponins were purchased from 
Shanghai yuanye Bio-Technology Co., Ltd (Shanghai, 
China). Chromatogram grade methanol and 
acetonitrile and the other reagents of AR grade were 
obtained from ANPEL Laboratory Technologies Inc. 
(Shanghai, China). Common reagents were purchased 
from Sigma Aldrich (Merck, Germany). Kunming 
mice, half male and half female, weighing 17 to 23 g 
were provided by the Experimental Animal Center of 
Guangxi University of Traditional Chinese Medicine.  
Separation and purification of Rg1 from panax notoginseng 
The separation and purification of Rg1 from Panax 
notoginseng was completed in following steps5: (i) 
Pretreatment of packing: Thin-layer chromatography 
silica gel was dried at 100 to 120°C for 24 h, followed 
by 150°C for 6 h. After cooling, the gel was ready for 
purification; (ii) Qualitative analysis by thin layer 
chromatography: The colour was developed with 10% 
thioacid using n-butanol: ethyl acetate: water in ratio 
of 4:1:5 as the developing solvent. Each group of 
fractions was subjected to thin-layer detection, and 
according to the Rf value, the fraction solutions were 
pooled; (iii) Quantitative analysis by liquid 
chromatography: Reference solution: Weigh 
accurately 1.00 mg of Rg1 reference substance, place 
them in a 10 mL volumetric flask, dissolve them with 
methanol, and then accurately pipette 1.0 mL into a 
10 mL volumetric flask, add methanol to volume, and 
then prepare a solution with mass concentration of 10 
μg/mL, and Test solution: Accurately weigh an 
appropriate amount of panax notoginseng saponins 
powder, place it in a 25 mL volumetric flask, use 
mobile phase to dissolve ultrasonic solubilization, 
fully dissolve it, and filter the microporous filter 
membrane for later use; and (iv) Preparation of 
standard curve: Accurately pipette 0.5, 1.0, 1.5, 2.0, 
and 2.5 mL of Rg1 reference solution (10 μg/mL) into 
10 mL volumetric flasks, respectively, then dilute to 
volume with methanol, and shake well. According to 
the above chromatographic conditions, accurately 
inject 20 μL into the liquid chromatograph, determine 
the peak area and draw the standard curve with the 
mass concentration (μg/mL) of the reference 
substance as the abscissa and the peak area as the 
ordinate. 
 
Effects of Rg1 on the blood glucose levels in normal mice 
Forty normal mice were randomly divided into 
normal control group and high, medium and low 
doses of Rg1 treated groups with 10 mice in each 
group12. Three Rg1 groups and normal control group 
were daily administered 0.5, 1.0, 1.5 mg/kg, and equal 
volume of distilled water with a dose volume of 20 
mL/kg for 7 days, respectively. Blood samples were 
collected from the orbital venous plexus of mice at 
0.5, 1.0 and 2 h after medication. The blood samples 
were centrifuged at 3500 rpm/min for 15 min after 
blood coagulation, followed by serum separation, and 
blood glucose levels were further measured using a 
Beckman Kurt automatic biochemical analyzer 
(Beckman, USA). 




Effects of Rg1 on blood glucose levels in hyperglycemic mice 
Fifty normal mice were randomly divided into 
normal control group, high glucose control group and 
high glucose groups administered with high, medium 
and low doses of Rg1 (0.5, 1.0 and 1.5 mg/kg), 
respectively, with 10 mice in each group8. Three Rg1 
groups were intragastrically administered once a day, 
and the high glucose control group and the normal 
control group were given an equal volume of distilled 
water with a dose volume of 20 mL/kg for 7 days. 
Blood glucose levels of mice in each group were 
measured in a manner as described above. 
 
Effects of Rg1 on blood glucose levels in hypoglycemic mice 
Fifty normal mice were randomly divided into 
normal control group, insulin control group and 
hypoglycemia group administered with high, medium 
and low doses of Rg1 (n = 10)8. Among them, three 
doses of Rg1 (0.5, 1.0 and 1.5 mg/kg) were 
intragastrically administered once a day, and the 
hypoglycemia group and the normal control group 
were given an equal volume of distilled water with a 
dose volume of 20 mL/kg for 7 days. After 
administration, except for the normal control group, the 
other groups of mice were intramuscularly injected 
with 0.5 U dose of insulin, and then the sample 
collection time-points of mice in each group, sampling 
and determination method were as described above. 
 
Statistical analysis 
All measured variables are presented as mean ± 
SD. Differences in all parameters were tested using 
one-way ANOVA. P values lower than 0.05 were 




Purification and characterization of Rg1 from P. notoginseng 
The normal phase silica gel column was used for 
the separation of Rg1 and a total of 115 bottles of 
volume 500 mL were collected. According to TLC 
detection, the fraction solutions with the same Rf 
value were combined to obtain four fractions. 
Fraction Zd1 is mainly a saponin with low polarity; 
fraction Zd2 mainly contains Rg1 with a retention 
time of 11.3 min and an area percentage ratio of 52%. 
The fraction Zd3 is mainly a highly polar saponin, 
and the fraction Zd2 were separated on silica gel 
column (6 × 60 cm) with 200 ~ 300 mesh, mobile 
phase dichloromethane:methanol in different ratios 
[100:3, 100:5, 100:8, 100:10], and 10 L solvent per 
gradient. As the elution curve shown in Fig. 1A, 
eluent of Rg1 was dichloromethane 2 methanol 
solution with a volume ratio of 10:1. The HPLC 
detection result showed in Fig. 1B revealed that the 
purity of Rg1 can be increased to 99.3%.  
 
Effect of notoginsenoside Rg1 on blood glucose levels in 
normal mice 
As shown in Table 1, the normal C57BL/6J mice 
intragastrically received PBS exhibited not significant 
changes in blood glucose level (BGL), and glucose 
level of the mice at 0.5 h also showed no obvious 
difference with the BGL of 1.0 and 2.0 h (P >0.05). 
 
 
Fig. 1 —Elution curve (A) and HPLC analysis (B) of Rg1 from 
Panax notoginseng 
 
Table 1— Effect of notoginsenoside Rg1 on blood glucose 
level in normal, hyperglycemic and hypoglycemic mice 
Groups Dose 
(mg/kg) 
Glucose level (mmol/L)  
0.5 h 1 h 2 h 
Normal mice 
Control PBS 6.9±0.5 6.4±0.8 6.5±0.9 
Rg1 0.5 6.8±1.1 6.1±1.0 6.7±1.3 
1.0 6.5±0.8 6.4±0.9 6.5±1.1 
1.5 6.3±0.6 6.5±1.2 6.6±0.8 
Hyperglycemic mice 
Normal PBS 6.4±0.9 6.6±0.8 6.5±1.2 
Control PBS 16.3±2.2 19.4±3.6 12.2±2.2 
Rg1 0.5 10.1±3.2* 11.2±1.4*** 6.8±1.7** 
 1.0 9.5±1.9* 10.4±1.5*** 5.9±1.5** 
 1.5 7.4±1.2*** 6.5±1.1*** 7.1±1.0*** 
Hypoglycemic mice 
Normal PBS 6.8±0.5 6.7±0.3 6.6±0.8 
Control PBS 2.9±0.1 3.4±0.1 3.9±0.2 
Rg1 0.5 4.2±0.5* 4.5±0.7 4.4±0.7* 
 1.0 5.8±0.8** 6.4±0.5** 5.9±0.6** 
 1.5 6.3±1.5*** 7.1±1.2*** 7.4±0.5*** 
[*, **, *** P <0.05, 0.02, 0.001 using one-way ANOVA vs.
control, respectively. All data are expressed as mean ± SD (n = 10)] 
 




Compared with the PBS control group, intragastric 
administration of Rg1 did not significantly change the 
BGLs of mice at three time points (0.5, 1.0 and 2.0 h) 
(P >0.05) indicating that gavage administration of 
Rg1 did not cause significant fluctuations in blood 
glucose in normal mice. 
 
Effect of notoginsenoside Rg1 on blood glucose levels in 
hyperglycemic mice 
Except the mice in normal group, all the other 
groups intragastrically received 2g/kg glucose at the 
late of medication. As is showed in Table 1, the BGLs 
of control mice remained stable during the entire 
experimental period, while those of the mice received 
Rg1 were all higher than 16 mmoL/L at 0.5 h, and 
peaked at 1.0 h, then decreased to 12.2 mmoL/L at 2.0 
h. Compared with the control group, intragastric 
administration of three doses of Rg1 significantly 
reduced the BGLs of mice at three time points (0.5, 
1.0 and 2.0 h) in a dose-dependent manner (P <0.05). 
Above results indicated that gavage administration of 
Rg1 could effectively ameliorate the hyperglycemia 
in the hyperglycemic mice. 
 
Effect of notoginsenoside Rg1 on blood glucose levels in 
hypoglycemic mice 
The five groups of mice, except the normal group, 
were intramuscularly injected with 0.5 U of insulin, 
followed by intragastric administration of PBS, 0.5, 
1.0 and 1.5 mg/kg of Rg1, respectively. Immediately 
0.5 h, 1.0 h and 2.0 h after drug administration, blood 
samples were obtained by orbital blood sampling to 
measure the BGLs of the mice in each group. As 
showed in Table 1, the blood glucose of mice in the 
control group after insulin injection were significantly 
lower than those of the mice in normal group with a 
minimum BGL of 2.9 mmol/L. However, the blood 
glucose changes of mice in the medium and high dose 
of Rg1 treated groups were not significant compared 
with the normal group, and the low dose group was 
still extremely significantly higher than the control 
group. The above results revealed that intragastric 
administration of Rg1 effectively improved the state 
of hypoglycemia in mice. 
 
Discussion 
Panax notoginseng has varying effects on the 
central nervous system, cardiovascular system, 
digestive system, immune system, endocrine system 
and genitourinary system, which can also improve the 
physical and intellectual activity and enhance the non-
specific resistance of the body to harmful stimuli2, 27. 
The pharmacological activity of Panax notoginseng 
often acts bi-directionally due to different functional 
states of the body, so it is a typical representative drug 
with “adaptogenic”-like effects2. 
 
According to different studies, notoginsenoside 
hold pharmacological activities and positive effects 
on many diseases, such as atherosclerosis, liver 
dysfunction, cerebrovascular disease, hypertension, 
menopausal syndrome, cancer and wound healing28-30. 
Additionally, it can exert therapeutic effects through 
different mechanisms, for example, notoginsenoside 
hypoglycemic could regulate the insulin secretion and 
transcription factors, control blood glucose level, 
improve insulin sensitivity and glucose transport31. 
Moreover, it can regulate immune function by 
controlling the production of cytokine, increasing the 
viability of T cells and restoring the function of T 
lymphocytes32,33. Furthermore, notoginseng can also 
exert anticancer effects through enhancing 
cytotoxicity, anti-tumor metastasis, inhibiting 
angiogenesis and acting in combination with other 
chemotherapeutic agents to reduce drug resistance29. 
 
Recently, it has been seen that both postprandial 
hyperglycemia and hypoglycemia induced by 
hypoglycemic drugs are the main causes of blood 
glucose fluctuation in patients with type 2 diabete34. 
Fluctuating hyperglycemia can promote endothelial 
cell apoptosis, and accelerate the damage of cell 
morphology and function via improving protein 
kinase C activity and simultaneously activating 
oxidative stress response19. At the same time, it 
significantly increases the risk of microangiopathy 
and cardiovascular death in patients with type 2 
diabetes35. Impaired blood glucose regulation 
mechanism in diabetic patients, combining with poor 
diet control, poor treatment compliance, improper 
medication and other factors, lead to significant blood 
glucose fluctuations especially the increase in blood 
glucose levels13.  
 
Current study showed that Panax notoginseng Rg1 
could effectively improve hyperglycemia induced by 
intragastric administration of glucose in mice and 
antagonized the glucose-increasing effect caused by 
glucose absorption in the body. Therefore, it was 
considered that Panax notoginseng Rg1 could reduce 
the level of hyperglycemia, reduce the fluctuations in 
blood glucose, and slow down the damage effect of 
blood glucose fluctuation on body cells in diabetic 
mice. Its mechanism of action may be related to 
hindering the absorption of glucose, promoting the 




utilization of glucose by peripheral tissues, and 
increasing the synthesis of glycogen. Although 
western medicine has hypoglycemic effects, however, 
it leads to hypoglycemia, lactic acidosis and other 
adverse reactions14. Panax ginseng based ginsenosides 
Rb2 regulates hepatic gluconeogenesis through AMP-
activated protein kinase (AMPK) and the orphan 
nuclear receptor small heterodimer partner (SHP) in 
hyperlipidemic conditions among in vitro model of 
type 2 diabetes36. On the other hand, hypoglycemia 
often indicates excessive glycemic excursions. The 
current clinical application confirm that the 
hypoglycemic effect of Chinese herbal medicine is 
stable and causes less adverse reactions37. 
Furthermore, current study investigated the effect of 
IHAE on blood glucose levels in normal mice, and the 
results showed that three doses of Panax notoginseng 
Rg1 had no significant effect on blood glucose levels 
in normal mice (P >0.05). Therefore, notoginseng 
Rg1 less often leads to too low blood glucose levels. 
 
Conclusion 
Current study showed that Panax notoginseng Rg1 
holds bidirectional regulatory effects on blood 
glucose in mice, which could reduce the level of 
hyperglycemia and increase the level of 
hypoglycemia, however, intragastric administration of 
Rg1 did not cause significantly significant 
fluctuations in blood glucose in normal mice. Thus, 
our findings further validated the bidirectional 
regulatory effects of Chinese herbal notoginseng Rg1 
saponin on blood glucose levels. However, further 
investigation of the effects of other components in 
Panax notoginseng saponins on blood glucose levels 
in mice might provide necessary significant support 
for the role of Panax notoginseng saponins in 
bidirectional glycemic control, and hence its use in 
diabetic conditions. 
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